Table 1.
Recipient, donor, and transplant characteristics (n = 106).
| Recipient | Donor | ||
|---|---|---|---|
| diS-HMGB1 | 413 ± 333 | Age (y) | 39 ± 16 |
| Age (y) | 57 ± 11 | Sex | |
| Sex | Female | 48 (45) | |
| Female | 45 (42) | Male | 58 (55) |
| Male | 61 (58) | Race | |
| Race | Asian | 7 (7) | |
| Asian | 8 (7) | Black/African American | 8 (8) |
| Black/African American | 5 (5) | White/Caucasian | 55 (52) |
| White/Caucasian | 42 (40) | Hispanic/Latino | 33 (31) |
| Hispanic/Latino | 48 (45) | Other | 3 (3) |
| Other | 3 (3) | Status | |
| Liver disease etiology | DBD | 102 (96) | |
| AIH | 5 (5) | DCD | 4 (4) |
| ALF | 3 (3) | Warm ischemia (min) | 52 ± 11 |
| EtOH | 29 (27) | Cold ischemia (h) | 7.6 ± 3.3 |
| HBV | 4 (4) | Cause of death | |
| HCV | 34 (32) | Trauma | 37 (35) |
| NAFLD/NASH | 19 (18) | CVS | 32 (30) |
| PBC | 2 (2) | Anoxia | 35 (33) |
| PSC | 4 (4) | Other | 2 (2) |
| Other/unknown | 6 (6) | DM | 20 (12) |
| LFTs, opening | HTN | 35 (22) | |
| AST | 1091 ±1007 | CAD | 6 (4) |
| ALT | 545 ± 492 | LFTs at procurement | |
| Bilirubin | 8 ± 6.2 | ALT | 58 ± 89 |
| INR | 1.5 ± 0.3 | Bilirubin | .95 ± 0.69 |
| Transplant liver type | |||
| Liver/kidney | 11 (10) | Transplant, Recipient + Donor | |
| Split right tri-segment | 1 (1) | LIRI | |
| Whole liver | 94 (89) | LIRI+ | 47 (44) |
| MELD at list | 26 ± 11 | LIRI − | 59 (56) |
| MELD at transplant | 33 ± 9 | ABO | |
| Identical | 95 (90) | ||
| Compatible | 11 (10) | ||
| Donor risk index | 1.49 ± 0.36 | ||
| Sharing | |||
| Local | 63 (59) | ||
| Regional | 41 (39) | ||
| National | 2 (2) |
Values are mean ± SD or n (%).
AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine transaminase; AST, aspartate aminotransferase; CAD, coronary artery disease; CVS, cerebral vasospasm; DBD, donation after brain death; DCD, donation after cardiac death; DM, diabetes mellitus; EtOH, alcohol-associated; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HTN, hypertension; INR, international normalized ratio; LFT, liver function test; LIRI, liver ischemia-reperfusion injury; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.